Caladrius Biosciences, Inc. (CLBS) Social Stream



Caladrius Biosciences, Inc. (CLBS): $0.54

0.01 (+2.31%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CLBS to Watchlist
Sign Up

Industry: Biotech


Ranked

of 449

in industry

Featured Post From StockTwits About CLBS

$CLBS IN CASE YOU FORGOT?
CLBS Stock Price Increases Over 130%

By Amit Chowdhry ● January 20, 2021 -(6 months ago)

The stock price of Caladrius Biosciences Inc. is trading up more than 130% pre-market today.

KEY QUOTES:
“We are extremely excited about our CLBS16 program. It represents a breakthrough in the treatment of CMD. Currently there are no products with approved labeling for coronary microvascular dysfunction.
— David J. Mazzo, PhD, President and Chief Executive Officer of Caladrius Hospital Health Network in Cincinnati, Ohio.

The 105-patient double-blind and placebo-controlled clinical trial was designed to further evaluate the efficacy and safety of intracoronary delivery of autologous CD34+ cells (CLBS16) in subjects with CMD and without obstructive coronary artery disease.

When a diagnosis of CMD is missed, patients are untreated and remain at elevated risk of heart risk or cardiovascular-related death.
Caladrius’ CLBS16 program has demonstrated great promise.
Mountainpose1, published August 16, 2021

Loading social stream, please wait...


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4339 seconds.